Glycosphingolipid depletion in PC12 cells using iminosugars protects neuronal membranes from anti-ganglioside antibody mediated injury.

Glycosphingolipid depletion in PC12 cells using iminosugars protects neuronal membranes from anti-ganglioside antibody mediated injury.

Autoimmune neuropathies are frequently associated with pathogenic anti-ganglioside antibodies targeting ganglioside-rich neuronal and glial membranes. The extent of injury is determined by the concentration of membrane ganglioside and thus reduction might be expected to attenuate disease. In this st...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Townson, K, Speak, A, Greenshields, K, Goodyear, C, Willison, H, Platt, F
Format:	Journal article
Język:	English
Wydane:	2008

Podobne zapisy

Ganglioside antibodies and neuropathies.
od: Rinaldi, S, i wsp.
Wydane: (2008)

Multi-system disorders of glycosphingolipid and ganglioside metabolism
od: You-Hai Xu, i wsp.
Wydane: (2010-07-01)

Correction of liver steatosis by a hydrophobic iminosugar modulating glycosphingolipids metabolism.
od: Elisa Lombardo, i wsp.
Wydane: (2012-01-01)

Characterization and quantitative determination of gangliosides and neutral glycosphingolipids in human liver.
od: O Nilsson, i wsp.
Wydane: (1982-02-01)

Glycosphingolipids in endocytic membrane transport.
od: Sillence, D, i wsp.
Wydane: (2004)

Generalized accumulation of neutral glycosphingolipids with GM2 ganglioside accumulation in the brain
od: Paul D. Snyder, Jr., i wsp.
Wydane: (1972-01-01)

A rapid and quantitative method for the isolation of gangliosides and neutral glycosphingolipids by DEAE-silica gel chromatography.
od: S K Kundu, i wsp.
Wydane: (1978-03-01)

Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff disease.
od: Karen M Ashe, i wsp.
Wydane: (2011-01-01)

Diverse endogenous antigens for mouse NKT cells: self-antigens that are not glycosphingolipids.
od: Pei, B, i wsp.
Wydane: (2011)

New GM1 Ganglioside Derivatives for Selective Single and Double Labelling of the Natural Glycosphingolipid Skeleton
od: Polyakova, S, i wsp.
Wydane: (2009)

Iminosugar inhibitors for treating the lysosomal glycosphingolipidoses
od: Butters, T, i wsp.
Wydane: (2005)

Introduction: Glycosphingolipids in cell biology and disease.
od: Sillence, D, i wsp.
Wydane: (2004)

Glycosphingolipid antigens from Leishmania (L.) amazonensis amastigotes: Binding of anti-glycosphingolipid monoclonal antibodies in vitro and in vivo
od: A.H. Straus, i wsp.
Wydane: (1997-03-01)

[Glycosphingolipids Gb3 and iGb3. In vivo roles in hemolytic-uremic syndrome and iNKT cell function].
od: Porubsky, S, i wsp.
Wydane: (2008)

Glycosphingolipids Gb3 and iGb3. In vivo roles in hemolytic-uremic syndrome and iNKT cell function
od: Porubsky, S, i wsp.
Wydane: (2008)

Substrate reduction therapy for glycosphingolipid storage disorders.
od: Lachmann, R, i wsp.
Wydane: (2001)

A Novel Iminosugar UV-12 with Activity against the Diverse Viruses Influenza and Dengue (Novel Iminosugar Antiviral for Influenza and Dengue)
od: Kelly L. Warfield, i wsp.
Wydane: (2015-05-01)

Regulation of membrane-bound enzymes of glycosphingolipid biosynthesis
od: J D Burczak, i wsp.
Wydane: (1984-12-01)

Neuraminidases 3 and 4 regulate neuronal function by catabolizing brain gangliosides
od: Pan, X, i wsp.
Wydane: (2017)

Glycosphingolipid dysregulation and lysosomal dysfunction in motor neuron disease
od: da Silva Santos, CS
Wydane: (2021)

Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis.
od: Jeyakumar, M, i wsp.
Wydane: (2002)

Anti-ganglioside antibodies and celiac disease
od: Alessandro Granito, i wsp.
Wydane: (2021-05-01)

The relationship between depletion of brain GM1 ganglioside and Parkinson's disease
od: Sandro Sonnino
Wydane: (2023-09-01)

New therapeutics for the treatment of glycosphingolipid lysosomal storage diseases.
od: Butters, T, i wsp.
Wydane: (2003)

Inhibition of glycosphingolipid biosynthesis: application to lysosomal storage disorders.
od: Butters, T, i wsp.
Wydane: (2000)

New developments in treating glycosphingolipid storage diseases.
od: Platt, F, i wsp.
Wydane: (2005)

Iminosugar for treatment of tumors
od: Dwek, R, i wsp.
Wydane: (2008)

Glycosphingolipid metabolism and its role in ageing and Parkinson’s disease
od: Wallom, K-L, i wsp.
Wydane: (2021)

Altered expression of ganglioside metabolizing enzymes results in GM3 ganglioside accumulation in cerebellar cells of a mouse model of juvenile neuronal ceroid lipofuscinosis
od: Somogyi, A, i wsp.
Wydane: (2018)

Ultrasound-mediated piezoelectric differentiation of neuron-like PC12 cells on PVDF membranes
od: Marcus Hoop, i wsp.
Wydane: (2017-06-01)

Iminosugar antivirals: the therapeutic sweet spot
od: Alonzi, D, i wsp.
Wydane: (2017)

Identification of GM1-Ganglioside Secondary Accumulation in Fibroblasts from Neuropathic Gaucher Patients and Effect of a Trivalent Trihydroxypiperidine Iminosugar Compound on Its Storage Reduction
od: Costanza Ceni, i wsp.
Wydane: (2024-01-01)

Iminosugars: promising therapeutics for influenza infection
od: Tyrrell, B, i wsp.
Wydane: (2016)

Profile in ganglioside antibodies in benign prostatic hyperplasia
od: Ilinca Nicolae, i wsp.
Wydane: (2016-03-01)

ALTERED AUTOPHAGY AND APP METABOLISM IN GLYCOSPHINGOLIPID STORAGE DISEASES
od: Boland, B, i wsp.
Wydane: (2011)

The mechanism of action of iminosugars as antiretrovirals
od: Spiro, S, i wsp.
Wydane: (2014)

The synthesis and biology of iminosugars and their precursors
od: Ayers, B, i wsp.
Wydane: (2014)

The synthesis of branched sugars and iminosugars
od: Parry, LL
Wydane: (2011)

Total asymmetric syntheses of iminosugars
od: Figuccia, A, i wsp.
Wydane: (2015)

Substrate deprivation: a new therapeutic approach for the glycosphingolipid lysosomal storage diseases.
od: Platt, F, i wsp.
Wydane: (2000)